Recent licensing of orally administered once daily sodium–glucose cotransporter‐2 (SGLT‐2) inhibitors in the UK now offers an alternative and potentially easier management strategy for cats with DM [22, 23, 24]. This evidence concerns the gene SLC5A2 and diabetes mellitus.